Last $5.86 USD
Change Today +0.29 / 5.21%
Volume 1.6M
NWBO On Other Exchanges
As of 5:20 PM 09/16/14 All times are local (Market data is delayed by at least 15 minutes).

northwest biotherapeutics (NWBO) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/14 - $10.64
52 Week Low
11/6/13 - $3.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

northwest biotherapeutics (NWBO) Related Businessweek News

No Related Businessweek News Found

northwest biotherapeutics (NWBO) Details

Northwest Biotherapeutics, Inc., a development stage biotechnology company, discovers and develops immunotherapy products to treat cancers in the United States and internationally. It is involved in the development of DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer. The company’s products include DCVax-L, which is under Phase III brain cancer trial for treating brain and ovarian cancer; DCVax-Direct that is under Phase I/II clinical for various types of inoperable solid tumor cancers; and DCVax-Prostate for late stage hormone independent prostate cancer. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

9 Employees
Last Reported Date: 04/1/14
Founded in 1996

northwest biotherapeutics (NWBO) Top Compensated Officers

Chairperson, Chief Executive Officer, Preside...
Total Annual Compensation: $360.0K
Founder, Chief Scientific Officer, Secretary ...
Total Annual Compensation: $295.7K
Senior Vice President of Clinical Research
Total Annual Compensation: $300.0K
Chief Technical Officer
Total Annual Compensation: $325.2K
Senior Vice President of Business Development
Total Annual Compensation: $348.0K
Compensation as of Fiscal Year 2013.

northwest biotherapeutics (NWBO) Key Developments

Northwest Biotherapeutics, Inc. announced delayed 10-Q filing

On 08/14/2014, Northwest Biotherapeutics, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Northwest Biotherapeutics Obtains Approvals for Enhancements of Phase Iii Trial of DCVax(R)-L for GBM Brain Cancer

Northwest Biotherapeutics announced that, following a nine-month process of regulatory submissions and reviews by regulators in the US, UK and Germany, it has obtained regulatory approvals to make certain enhancements to its ongoing Phase III clinical trial of DCVax-L Glioblastoma multiforme (GBM) brain cancer. The enhancements will allow the statistical analysis of trial results to take account of a major new variable which has been identified in GBM research since the Company's Phase III trial began, and will lower the threshold for satisfying the primary endpoint of the trial. The company has been blinded at all times, with no access to any data in the Phase III trial, and will remain fully blinded until the trial is completed. The changes relate to the statistical analyses that will be done at the end of the trial, and do not affect the treatment protocol, dosing, randomization of patients or other such aspects. The changes were driven solely by external factors -- particularly research reports about a newly discovered variable which has been found to significantly affect GBM patients' survival times, and which the Company recognized could significantly skew the clinical trial results if the trial's statistical analyses did not control for it. The Company's Phase III trial design and statistical analyses already controlled for key variables known at the time when the trial was designed, such as a particular genetic factor (referred to as MGMT methylation), the extent of tumor removal, and others. The new variable involves the level of certain white blood cells in GBM patients when they finish the 6 weeks of daily radiation to the brain which is part of the current standard of care treatment. Important recent research has found that as many as 40% of GBM patients have such severely depressed white blood cell counts following radiation that their level is comparable to the level at which AIDs patients are put on continuous antibiotic treatments, prophylactically. Further, this research has found that these GBM patients' white blood cell counts do not recover with the passage of time. Most importantly, the recent research has identified a major impact on these GBM patients' Overall Survival (OS): the variable relating to severe depression of white blood cell counts can make a difference of 6 months in OS. As a comparison, the standard of care drug for GBM, Temodar, only makes a difference of 10 weeks in OS. If the statistical analysis of GBM trial results does not take account of such a major variable, the overall trial results could be significantly skewed. Under the enhancements to NW Bio's Phase III trial, the statistical analyses of the trial results will be modified to take account of, and control for, this important new variable. Also under the enhancements, the threshold for satisfying the primary endpoint of the Phase III trial (which is Progression Free Survival, or PFS) will be lowered from requiring a 6-month difference to requiring only a 4-month difference between the PFS of the patients treated with DCVax-L and the PFS of patients in the control arm of the trial. The bases for reducing the threshold from 6 months to 4 months difference in PFS include increasing the total number of patients in the trial from 312 to 348, and increasing the number of "events" that will be counted in the statistical analyses at the end of the trial. An "event" is a tumor recurrence or a patient death. The current trial plan involves counting 110 "events" from among the 312 total patients in the trial to evaluate whether the primary endpoint is met. Under the enhancements of the trial, 248 "events" will be counted from the 348 total patients in the trial to evaluate whether the PFS primary endpoint is met. By increasing the number of "events" counted, the statistical basis of the trial, which is already quite strong, will be further strengthened. As a result, it is anticipated that a 4-month difference in PFS will be sufficient to reach the strong "p value" planned in the trial (0.02), and it will not be necessary to show a 6-month difference in PFS. ("p value" is a measure of statistical significance -- the probability that trial results are due to chance, rather than the effects of the treatment. So, the smaller p value, the stronger the significance. Regulatory authorities generally require that the p value of trial results be 0.05 or lower for product approvals.). The company has obtained approval from the US FDA and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and conditional approval from the German regulatory authority (the Paul Ehrlich Institute, or PEI). The Company is now working toward the final approval from the PEI. The trial enhancements will also have to go through Institutional Review Board (IRB) review and approval at each of the clinical trial sites. There are currently over 50 trial sites in operation in the US and a number of sites in operation in the UK and Germany. There will also be certain other requirements for implementation of the changes, modified documentation and procedures. Taking into account the time required for these approvals and implementation steps, and the 36-patient increase in the trial, as well as the gradual ramp-up of the trial in Europe, the Company currently anticipates that enrollment will be completed in approximately Third Quarter of next year, and the primary endpoint of the trial will be reached about 3-5 months after full enrollment or by around year-end of 2015.

Northwest Biotherapeutics, Inc. Announces Completion of DCVax(R)-Direct Phase I Trial Recruitment

Northwest Biotherapeutics, Inc. announced that the Phase I portion of the company's Phase I/II DCVax-Direct clinical trial has completed its 36-patient target recruitment and the company is now underway with preparations for the Phase II portion of this trial, as well as expansion of DCVax-Direct manufacturing. The Phase I/II trial is testing the safety and activity of DCVax-Direct in various types of cancer. The Phase I portion of the trial has involved testing of 3 different dose levels, and a diverse range of cancers. The patients enrolled in Phase I will continue to receive treatments in accordance with the protocol. With the closing of Phase I, the company is now preparing to initiate the Phase II portion of the trial. This second part of the Phase I/II study will target 24 or more patients in selected cancers. Additional trial sites are being brought on to facilitate and expedite enrollment.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWBO:US $5.86 USD +0.29

NWBO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWBO.
View Industry Companies

Industry Analysis


Industry Average

Valuation NWBO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 799.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 803.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NORTHWEST BIOTHERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at